MedTrace Logo

Higher vs. Lower Dose Heparin for PCI

NCT04049591 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16000

Last updated 2025-07-31

No results posted yet for this study

Summary

HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

Higher Dose UFH

Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures

DRUG

Lower Dose UFH

Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Sanjit Jolly, MD · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2024-10-08
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049591 on ClinicalTrials.gov